Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman and Man Max 99 years
Sanofi Pasteur MSD
Update Il y a 4 ans
Comparison of the immunogenicity and safety of a combined adsorbed low dose diphtheria, tetanus and inactivated poliomyelitis vaccine (REVAXIS®) with a combined diphtheria, tetanus and inactivated poliomyelitis vaccine (DT Polio®) when given as a booster dose at 6 years of age
To demonstrate that the Diphtheria seroprotection response (defined as anti-diphtheria antibody titre (SN) ≥ 0.1 IU/mL), the Tetanus seroprotection response (defined as an anti-tetanus antibody titre ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A NON-INVASIVE EVALUATION OF BONE MICROARCHITECTURE MODIFICATION IN OSTEOPENIC POSTMENOPAUSAL WOMEN BY 3D-PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY : A 24-MONTH, MONOCENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY COMPARING WEEKLY ORAL RISEDRONATE 35 MG AND PLACEBO
The primary objective of this study is to compare risedronate 35 mg and placebo with respect to percent change at 12-month for distal radius trabecular bone volume (BV/TV) in osteopenic postmenopausa...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A 24-week, open, multicenter, comparative study of 2 strategies (including insulin glargine versus premixed insulin) for the therapeutic management of patients with type 2 diabetes failing oral agents
The primary objective of this study is to demonstrate the superiority of a strategy with insulin glargine in comparison with a strategy including the premixed insulin in term of percentage of patients...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Étude TCD14678 : étude de phase 1-1b randomisée évaluant la tolérance, la pharmacocinétique, la pharmacodynamique et l’activité antitumorale du SAR439459 en monothérapie et en association avec du REGN2810, chez des patients ayant une tumeur solide avancée ou un mélanome après échec d’un traitement par anticorps anti-PD1 ou anti-PDL1.
Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquents puisqu’ils représentent 90% des cancers humains. On distingue 2 type...
Country
France
organs
Tumeurs solides
,
Mélanomes cutanés
Specialty
Immunothérapie - Vaccinothérapie
,
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A “Real World” Trial to determine efficacy and health outcomes of TOUJEO compared to “standard of care” basal insulins in insulin naïve patients intiating insulin
To demonstrate non-inferiority of Toujeo versus “standard of care” basal insulin therapy measured as glycosylated hemoglobin (HbA1c) change.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fasting blood glucose with or without other comorbidities
To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of 12 months when presc...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
A multicenter, Randomized, Double Blind, Double Dummy, Parallel Group, Dose Ranging Study of subcutaneous SR123781A with an Enoxaparin calibrator arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement surgery
To demonstrate the efficacy of SR123781A in the prevention of Venous Thromboembolism (DVTand/or PE) via demonstration of a dose-response in patients undergoing total hip replacement surgery
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Safety and immunogenicity of an intramuscular, inactivated, split-virion, pandemic influenza A/H5N1 vaccine in adults and the elderly
• To describe the injection site reactions and systemic safety profile during the 21 days following each of two primary series and one booster (as applicable) intramuscular (IM) injections in two age ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of the concomitant use of a live pentavalent rotavirus vaccine (RotaTeq®) and a meningococcal group C conjugate (MCC) vaccine in healthy infants
To demonstrate that RotaTeq® can be administered concomitantly with MCC vaccine to healthy infants without impairing the antibody seroprotection rate to meningococcal Group C serotype as measured by s...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children
• To describe the safety profiles (injection site reactions and systemic events) during the 21 days following each vaccination in subjects receiving the D0-D21 and the D0-D42 vaccination schedules, an...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
8
9
10
11
12
13
14
15
16
17
Next